Lite Strategy Inc (LITS)

$2.69 -0.22 (-7.56%)
Market Cap 95.56M
Revenue (ttm) 65.30M
Net Income (ttm) 17.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 27.23%
Debt to Equity Ratio 0.00
Volume 1,746,600
Avg Vol 1,878,838
Day's Range N/A - N/A
Shares Out 32.84M
Stochastic %K 1%
Beta 0.38
Analysts Hold
Price Target N/A
Latest News on LITS
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'

Sep 10, 2025, 9:00 AM EDT - 6 days ago

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

Aug 5, 2025, 8:00 AM EDT - 6 weeks ago

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

Jul 24, 2025, 8:00 PM EDT - 7 weeks ago

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Jul 22, 2025, 4:35 PM EDT - 2 months ago

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Why Is MEI Pharma Stock Soaring On Friday?

Jul 18, 2025, 1:22 PM EDT - 2 months ago

Why Is MEI Pharma Stock Soaring On Friday?

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Jul 18, 2025, 8:30 AM EDT - 2 months ago

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

May 13, 2025, 4:05 PM EDT - 4 months ago

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

Feb 12, 2025, 4:12 PM EST - 7 months ago

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

Nov 12, 2024, 4:05 PM EST - 11 months ago

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

MEI Pharma Reports Fiscal Year End 2024 Cash Position

Sep 19, 2024, 4:01 PM EDT - 1 year ago

MEI Pharma Reports Fiscal Year End 2024 Cash Position

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

Aug 12, 2024, 8:30 AM EDT - 1 year ago

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

MEI Pharma to Consider Strategic Alternatives

Jul 22, 2024, 8:30 AM EDT - 1 year ago

MEI Pharma to Consider Strategic Alternatives

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

May 14, 2024, 10:38 AM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

May 9, 2024, 4:02 PM EDT - 1 year ago

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

Apr 11, 2024, 8:02 AM EDT - 1 year ago

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

Apr 11, 2024, 8:00 AM EDT - 1 year ago

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Apr 10, 2024, 8:00 AM EDT - 1 year ago

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Mar 26, 2024, 8:00 AM EDT - 1 year ago

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Feb 13, 2024, 5:05 PM EST - 1 year ago

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

Jan 16, 2024, 5:00 PM EST - 1 year ago

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Dec 11, 2023, 12:00 PM EST - 1 year ago

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

Nov 9, 2023, 4:05 PM EST - 2 years ago

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

Nov 6, 2023, 4:57 PM EST - 2 years ago

MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

Nov 2, 2023, 9:00 AM EDT - 2 years ago

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

Nov 1, 2023, 9:00 AM EDT - 2 years ago

MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

MEI Pharma Recommends Stockholders Not to Consent

Oct 17, 2023, 5:33 PM EDT - 2 years ago

MEI Pharma Recommends Stockholders Not to Consent

MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

Oct 2, 2023, 6:00 AM EDT - 2 years ago

MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions

Sep 28, 2023, 5:00 PM EDT - 2 years ago

MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions

MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript

Sep 26, 2023, 7:47 PM EDT - 2 years ago

MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

Sep 26, 2023, 4:02 PM EDT - 2 years ago

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

Sep 21, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023

MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car

Sep 18, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

Aug 16, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma Announces Results of Special Meeting of Stockholders

Jul 23, 2023, 2:30 PM EDT - 2 years ago

MEI Pharma Announces Results of Special Meeting of Stockholders

MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

Jul 19, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

MEI Pharma Responds to Anson and Cable Car

Jul 18, 2023, 9:00 AM EDT - 2 years ago

MEI Pharma Responds to Anson and Cable Car

MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

Jul 17, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

MEI Pharma Postpones Special Meeting of Shareholders

Jul 13, 2023, 4:05 PM EDT - 2 years ago

MEI Pharma Postpones Special Meeting of Shareholders

MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

Jul 11, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals

Jul 7, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals

ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

Jul 5, 2023, 8:30 AM EDT - 2 years ago

ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals

Jul 5, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals

MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

Jun 29, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

Jun 15, 2023, 12:08 PM EDT - 2 years ago

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

Jun 14, 2023, 7:01 PM EDT - 2 years ago

INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

Jun 13, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D.

Jun 2, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D.

MEI Pharma Board of Directors Rejects Unsolicited Proposal

Jun 1, 2023, 8:00 AM EDT - 2 years ago

MEI Pharma Board of Directors Rejects Unsolicited Proposal

MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal

May 30, 2023, 5:40 PM EDT - 2 years ago

MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal